October 27, 2016
Verlyx Pharma announces new data on VLX103 to be presented at the AASLD 2016 Annual Liver Meeting
- Three abstracts accepted for poster presentations
- VLX103 is effective in a well established NASH mouse model
- VLX103 is clinically safe and hepatoselective in liver disease patients
Montreal – October 27, 2016 – Verlyx Pharma Inc., a specialty pharmaceutical company developing innovative therapies for the treatment of liver diseases, is pleased to announce the presentation of three posters, all related to its lead product VLX103, at The Liver Meeting® 2016, the 67th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) to be held in Boston on November 11-15, 2016.
The presentations will highlight the properties of VLX103 which make it particularly attractive for the treatment of liver diseases. Strong preclinical and clinical findings confirm the promising therapeutic profile of Verlyx’s lead compound.
Poster #641, “Clinical evidence of hepatoselectivity of oral pentamidine (VLX103) in cirrhotic patients with early stage hepatocellular carcinoma”, and Poster #642, “Clinical safety and pharmacodynamics of VLX103, a new orally administered pentamidine formulation, in cirrhotic patients with early stage hepatocellular carcinoma” will be displayed in the Poster Hall, Hall C of the Hynes Convention Center on Friday, November 11, from 8:00 a.m. to 5:30 p.m., with presenters available for discussion at the posters from noon to 1:30 p.m.
Poster #1611, “Oral pentamidine (VLX103) is an effective treatment for high fat diet-induced NASH in mice” will be displayed in the Poster Hall, Hall C of the Hynes Convention Center on Sunday, November 13, 2016, from 8:00 a.m. to 5:30 p.m., with presenters available for discussion at the poster from 12:30-2:00 pm.
“The data being presented at The Liver Meeting® provide further evidence of the therapeutic potential of our lead compound in the treatment of inflammatory liver diseases such as NASH, and continue building up on our clinical database of support for VLX103’s pharmacology and safety,” said Pierre Falardeau, President and CEO of Verlyx Pharma. “We are excited to advance our clinical development for VLX103 in both NASH and ASH, for which no approved treatment is currently available,” added Dr Falardeau.
About Verlyx Pharma
Verlyx Pharma Inc. is a specialty pharmaceutical company focused on the development of innovative therapies for the treatment of liver diseases with high unmet needs. Verlyx’s lead product, VLX103, is a proprietary oral product that combines hepatoselective and hepatoprotective properties. The company is conducting a comprehensive research and development program aimed at important unmet needs in the field of liver diseases, including Non-Alcoholic Steatohepatitis (NASH) and Alcoholic Steatohepatitis (ASH). Additional information about the company can be obtained on its website: www.verlyx.com.